Testing effectiveness (Phase 2)Study completedNCT03207347
What this trial is testing
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
Who this might be right for
MesotheliomaUveal MelanomaRenal Cell Carcinoma+1 more
University of Florida 37